AU2018335837A1 - Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides - Google Patents

Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides Download PDF

Info

Publication number
AU2018335837A1
AU2018335837A1 AU2018335837A AU2018335837A AU2018335837A1 AU 2018335837 A1 AU2018335837 A1 AU 2018335837A1 AU 2018335837 A AU2018335837 A AU 2018335837A AU 2018335837 A AU2018335837 A AU 2018335837A AU 2018335837 A1 AU2018335837 A1 AU 2018335837A1
Authority
AU
Australia
Prior art keywords
composition
polypeptide
sfgfr3
fgfr3
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018335837A
Other languages
English (en)
Inventor
Stéphanie GARCIA
Elvire Gouze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Université Côte d'Azur
Pfizer Inc
Original Assignee
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Université Côte d'Azur
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université Côte d'Azur, Pfizer Inc filed Critical Centre National de la Recherche Scientifique
Publication of AU2018335837A1 publication Critical patent/AU2018335837A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018335837A 2017-09-20 2018-09-20 Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides Abandoned AU2018335837A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762561140P 2017-09-20 2017-09-20
US62/561,140 2017-09-20
PCT/EP2018/075471 WO2019057820A1 (en) 2017-09-20 2018-09-20 ABNORMAL VISCERAL GREASE DEPOSITION TREATMENT USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES

Publications (1)

Publication Number Publication Date
AU2018335837A1 true AU2018335837A1 (en) 2020-04-23

Family

ID=63878625

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018335837A Abandoned AU2018335837A1 (en) 2017-09-20 2018-09-20 Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides

Country Status (12)

Country Link
US (1) US20200297799A1 (enExample)
EP (1) EP3684394A1 (enExample)
JP (1) JP7335247B2 (enExample)
KR (1) KR20200103621A (enExample)
CN (1) CN111836634A (enExample)
AU (1) AU2018335837A1 (enExample)
BR (1) BR112020005459A2 (enExample)
CA (1) CA3076396A1 (enExample)
IL (1) IL273203A (enExample)
MX (1) MX2020003114A (enExample)
PH (1) PH12020550461A1 (enExample)
WO (1) WO2019057820A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
NL2020176B1 (en) * 2017-12-22 2019-07-02 Van Der Hoeven Horticultural Projects B V Greenhouse
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法
WO2024147597A1 (ko) * 2023-01-03 2024-07-11 서울대학교산학협력단 Fgfr3 발현 또는 활성 억제제의 퇴행성 신경질환 치료 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109850A1 (en) * 2000-12-18 2004-06-10 Neelam Jaiswal Treatment of bone disorders by modulation of fgfr3
US20150344855A1 (en) * 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
RS60593B1 (sr) * 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
CA2972865A1 (en) * 2015-01-07 2016-07-14 Therachon Sas Soluble fgfr3 decoys for treating skeletal growth disorders
KR102432192B1 (ko) * 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도

Also Published As

Publication number Publication date
EP3684394A1 (en) 2020-07-29
WO2019057820A1 (en) 2019-03-28
BR112020005459A2 (pt) 2020-09-29
JP2020534367A (ja) 2020-11-26
IL273203A (en) 2020-04-30
US20200297799A1 (en) 2020-09-24
RU2020113712A3 (enExample) 2022-01-14
JP7335247B2 (ja) 2023-08-29
MX2020003114A (es) 2020-10-20
KR20200103621A (ko) 2020-09-02
CN111836634A (zh) 2020-10-27
CA3076396A1 (en) 2019-03-28
PH12020550461A1 (en) 2021-03-22
RU2020113712A (ru) 2021-10-20

Similar Documents

Publication Publication Date Title
US11697678B2 (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
JP7335247B2 (ja) 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置
US11814654B2 (en) Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
EP3828198A1 (en) Soluble fgfr3 decoys for treating skeletal growth disorders
RU2794170C2 (ru) ЛЕЧЕНИЕ АНОМАЛЬНОГО ОТЛОЖЕНИЯ ВИСЦЕРАЛЬНОГО ЖИРА С ИСПОЛЬЗОВАНИЕМ РАСТВОРИМЫХ ПОЛИПЕПТИДОВ РЕЦЕПТОРА ФАКТОРА РОСТА ФИБРОБЛАСТОВ 3 (sFGFR3)
JP2020015733A (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
HK40039240A (en) Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
WO2025117857A2 (en) Adp-ribosylation factor compositions and methods of use thereof
NZ790135A (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application